




2023 Latin America Conference on Lung Cancer

JANUARY 25-27, 2023
MONTEVIDEO, URUGUAY

PROGRAM BOOK



#LALCA23





**2023 Targeted Therapies
of Lung Cancer Meeting**

FEBRUARY 22-25, 2023 | SANTA MONICA, CALIFORNIA

REGISTER NOW!

#TTLC23
ttlc2023.org

**Learn more about virtual attendance
at <https://ttlc2023.iaslc.org/>**

Table Of Contents

Welcome Message 5

Venue Floorplan 8

Program 10

WEDNESDAY, JANUARY 25, 2023
THURSDAY, JANUARY 26, 2023
FRIDAY, JANUARY 27, 2023

Poster Listing 16

Education Awards 20

**Industry Supporters
& Exhibitors** 22

General Information 25



International Conference Services

MEETING SECRETARIAT

International Conference Services Ltd. (ICS)

Suite 710, 1201 West Pender Street, Vancouver, BC, Canada, V6E 2V2

Phone: +1 604 681 2153

www.icsevents.com

GLOBAL OFFICES

Vancouver, Toronto, Texas, London, Barcelona, Vienna, Tokyo, Singapore



01



Welcome Message



#LALCA23



Welcome Message

Dear Colleagues and Friends,

Welcome to the IASLC 2023 Latin America Conference on Lung Cancer taking place January 25 – 27, 2023 at the Radisson Hotel Montevideo Victoria Plaza in Montevideo, Uruguay. Lung Cancer is still the leading cause of death not only in Latin America but worldwide. Building on the success of previous Latin America Conferences on Lung Cancer (LALCA) international and national speakers will discuss the science and advances in the treatment and prevention of lung cancer and thoracic malignancies worldwide and Latin America in particular over the next few days.

With tobacco being the leading cause of morbid-mortality worldwide, the Conference will once again host a Cancer Control Program and Tobacco Forum, scheduled for Wednesday, January 25. The program will discuss important topics in lung cancer such as, but not limited to, development in surgery, radiotherapy innovations, targeted therapy, immunotherapy, and many more. We will continue with the very successful Round Table Discussions providing delegates a very unique opportunity to talk to and discuss directly with international leaders and local experts on specific topics.

We can't wait to see you all!

LALCA 2023 Meeting Co-Chairs



Luis Ubillos
MD, PhD

LALCA 2023 Co-Chair,
Uruguay



Mario Varangot
MD

LALCA 2023 Co-Chair,
Uruguay



Clarissa Mathias
MD

LALCA 2023 Co-Chair,
Brazil



Carlos Barrios
MD

LALCA 2023 Co-Chair,
Brazil

LATAM Group Co-Chairs



Luis E. Raez
MD, FACP, FCCP

LATAM Group Chair,
United States



Edgardo S. Santos
MD, FACP

LATAM Group Chair,
United States



Christian Rolfo
MD, PhD

LATAM Group Chair,
United States

The current state-of-the-art in lung cancer

Register by 25 January 2023



IMPORTANT DEADLINES

17 January 2023	Abstract submission
25 January 2023	Early registration
1 March 2023	Late registration

**COPENHAGEN DENMARK
29 MARCH - 1 APRIL 2023**

At this year's innovative LIVE Plus format, you will be able to review the current state-of-the-art in lung cancer therapy, update your knowledge in prevention, screening, detection and much more.

**Register by 25 January 2023 and
benefit from advantageous fees.**

Organisers



Partners



esmo.org



03



Venue Floorplan




#LALCA23



Venue Floorplan

Radisson Hotel Montevideo Victoria Plaza - 2nd Floor



04

Program

#LALCA23



Full Program

WEDNESDAY | JANUARY 25, 2023

09:00-15:00 IASLC School of Pathology

Grand Ballroom C2

09:00 Welcome Session

Chairs: Ignacio Wistuba, United States, Maria Arcila, United States

Principles and Methods: Surgical Pathology

Chair: Ignacio Wistuba, United States

09:05 Maximizing Tissue Utilization

Christina Fernandez, Chile

09:25 Choosing Best Tissue for Molecular Studies

Fabio Tavora, Brazil

09:45 Immunohistochemical Studies and FISH

Sergio Sanchez, México

10:05 Discussion

Principles and Methods: Molecular Track – Tumor Tissue Testing

Chair: Ignacio Wistuba, United States

10:45 Review of Guidelines

Mercedes Liliana Dalurzo, Argentina

11:05 Molecular Studies – Technology

Isabela Werneck da Cunha, Brazil

11:25 Single Gene vs Panel vs NGS

Valeria Denninghoff, Argentina

11:45 Discussion

12:00 - 13:00 Lunch Break

Principles and Methods: Molecular Track – Liquid Biopsy Testing

Chair: Maria Arcila, United States

13:00 Plasma Testing vs Tissue

Christian Rolfo, United States

13:20 Other Liquid Biopsies – Body Fluids and Their Value

Maria Arcila, United States

13:40 Discussion

Applications - Case studies - Outlining the Latin American Experience

Chair: Maria Arcila, United States

14:00 Outline Challenges in Interpreting PDL1 Stains

Fabio Tavora, Brazil

14:10 Outline Challenges in Working with very Minimal Tumor Tissue – Low Tumor Content and Low Tissue Content

Ricardo Armisen, Chile

14:20 Outline the Use of Cell Free DNA – Limitations, Benefits

Sergio Sanchez, México

14:30 Outline the Role of Evolving Biomarkers

Maria Arcila, United States

14:40 Discussion

09:15-15:00 IASLC School of Thoracic Oncology

Grand Ballroom C1

09:00 Welcome Session

Chairs: Norma Graciela Pilnik, Argentina, Edgardo Santos, United States, Luis Ubillos, Uruguay

09:15 Knowing IASLC: Why I Need to Be Part?

Heather Wakelee, United States

09:30 LATAM Activities

Luis Ubillos, Uruguay

09:45 Clinical Research in Lung Cancer: Gaps and Opportunities

Andres Cardona, Colombia

10:15 Planning a Career in Lung Cancer – Academia Practice

Norma Graciela Pilnik, Argentina

10:40 Planning a Career in Lung Cancer – Private Practice

Luis Corrales, Costa Rica

11:00 How to Become a Translational Physician

Christian Rolfo, United States

11:20 Clinical Research in the Community Setting

Luis Corrales, Costa Rica

11:35 Publish Your Research: Knowing the Process

Karen Kelly, United States

12:00 - 13:00 Lunch Break

13:00 Updating Your CV and Personal Statement

Luis Ubillos, Uruguay

13:15 Establishing a Basic Lab: Minimal Requirements

Rafael Rosell, Spain

13:30 Partnership Academia – Pharma: How to Navigate?

Edgardo Santos, United States

13:45 Radiation and Medical Oncologists Doing Research Together in LATAM: A Mirage?

Beatriz Amendola, United States

14:00 Building A Strong Thoracic Program: The Beauty of Multidisciplinary Team

Ricardo Sales dos Santos, Brazil

14:15 A Grant: How to Write and Get it?

Rafael Rosell, Spain

14:35 Wrap up and Adjourn

15:00-16:00 Living Room

Grand Ballroom C2

15:00 Diagnosing and Treating Lung Cancer in Latin America

Luis E. Raez, United States

16:00-17:00 Cancer Control Program and Tobacco Forum

Grand Ballroom C1

Chairs: Denisse Bretel, Perú, Elizabeth Ravera, United States

16:00 Implementing Interventions for Tobacco Control: Research-based Policies

Carlos Gil Ferreira, Brazil

16:15 Importance of Smoking Cessation in the Treatment of Lung Cancer Patient

Lucia Viola, Colombia

WEDNESDAY | JANUARY 25, 2023

16:30 Framework Convention in WHO in LATAM

Paulo César Correa, Brazil

16:45 Discussion

17:00-18:00 Lung Cancer Screening

Grand Ballroom C2

Chairs: Gelenis Domingo, United States, Luis Corrales, Costa Rica

17:00 Establishing Lung Cancer Screening as Standard of Care

Luis Corrales, Costa Rica

17:15 Incidental Pulmonary Programs as a Complement for Lung Cancer Screening

Lucia Viola, Colombia

17:30 Lung Cancer Screening in Latin America: Challenges and Progress

Ricardo Sales dos Santos, Brazil

17:45 Discussion

18:00-18:45 IASLC/LATAM General Meeting

Grand Ballroom C1

Chairs: Luis E. Raez, United States, Christian Rolfo, United States, Edgardo Santos, United States

19:00-19:30 Opening Ceremony

Grand Ballroom C1

Chairs: Carlos Barrios, Brazil, Clarissa Mathias, Brazil, Luis Ubillos, Uruguay, Mario Varangot, Uruguay

19:30-20:30 Welcome Reception

Grand Ballroom C3

THURSDAY | JANUARY 26, 2023

08:30-09:30 SS.01: Diagnostic Imaging Innovation

Grand Ballroom C1

Chair: Margarita Garcia Fontes, Uruguay

08:30 EBUS and Navigation System to Yield a Diagnosis

Lucia Viola, Colombia

08:45 Robotic Bronchoscopy in Lung Cancer

Francisco Tarrazzi, United States

09:15 Discussion

08:30-09:30 SS.02: Early Career Session & Research Vision

Grand Ballroom C2

Chairs: Denisse Bretel, Perú, Christian Caglevic, Chile

08:30 How to Write a Manuscript and a Research Grant

Carlos Gil Ferreira, Brazil

08:45 How to Incorporate Research in Latin America

Carlos Barrios, Brazil

09:00 The Role of Medical School to Promote Basic and Clinical Research

Norma Graciela Pilnik, Argentina

09:15 Discussion

09:30 - 10:30 Networking Break and Poster Viewing | Grand Ballroom C3

Refreshments will be provided

10:30-11:30 SS.03: Lung Cancer Pathology in the Era of Targeted Therapy

Grand Ballroom C1

Chairs: Mercedes Liliana Dalurzo, Argentina

10:30 Tissue Quality Control for Molecular Testing

Maria Arcila, United States

10:45 New Massive Parallel Sequencing Platforms (NGS) Versus Tailored Panels (ddPCR)

Ignacio Wistuba, United States

11:00 Molecular Markers in SQCC

Alberto Chiappori, United States

11:15 Discussion

10:30-11:30 SS.04: Novel Diagnostic and Prognostic Markers

Grand Ballroom C2

Chairs: Edgardo Santos, United States, Tannia Soria Samaniego, Ecuador

10:30 The Future of ctDNA

David R. Gandara, United States

10:45 Moving NGS in Liquid Biopsies to the Front Lines and Assessing Resistance Genomic Aberrations

Luis E. Raez, United States

11:00 New Technologies for Liquid Biopsies (Methylation, Exosomes, ECVs and CTCs)

Christian Rolfo, United States

11:15 Discussion

11:45-12:45 SS.05: New Developments in Surgery

Grand Ballroom C1

Chairs: Edgar Amorin, Perú, Ricardo Sales dos Santos, Brazil

11:45 Invasive Mediastinal Staging and Navigation (Mediatinoscopy, EBUS, EUS)

Ricardo Mingarini Terra, Brazil

12:00 VATS, Robot-Assisted or Thoracotomy for Lung Cancer Surgery

Ricardo Sales dos Santos, Brazil

12:15 Sub-lobar Resection for Stage I NSCLC

Francisco Tarrazzi, United States

12:30 Discussion

THURSDAY | JANUARY 26, 2023

11:45-12:45 **SS.06: Adjuvant Therapy in the Molecular Era**

Grand Ballroom C2

Chairs: Carlos Gil Ferreira, Brazil, Ticiana Leal, United States

- 11:45 Prognostic and Predictive Markers for Adjuvant Therapy NSCLC**
David Carbone, United States
- 12:00 Targeted Agents in the Adjuvant Setting**
Edgardo Santos, United States
- 12:15 Immunotherapy in Lung Cancer Adjuvant Setting**
Claudio Martin, Argentina
- 12:30 Discussion**

13:00 - 14:00 Lunch Break I Grand Ballroom C3 *Refreshments will be provided*

13:00-14:00 Industry Symposium Sponsored by Caris Life Sciences: Upfront Broad Profiling Improves Outcomes In NSCLC

Grand Ballroom C1

- 13:00 Welcome**
Vasanti Natarajan, Switzerland
- 13:05 Upfront Broad Profiling Improves Outcomes in NSCLC**
Luis Raez, United States
- 13:30 Case Discussion**
Edgardo Santos, United States
- 13:50 Q&A with panel and audience**

13:00-14:00 Industry Symposium Sponsored by Varian: Truebeam Technology for the Treatment of Lung Tumors

Grand Ballroom C2

- 13:00** Beatriz Amendola, United States

14:15-15:15 **SS.07: Radiotherapy Innovations**

Grand Ballroom C1

Chair: Arthur Accioly Rosa, Brazil

- 14:15 SBRT for Oligometastatic Disease**
Beatriz Amendola, United States
- 14:30 Role of SBRT in Early Stage NSCLC**
Gustavo Sarria, Perú
- 14:45 High Technology in Radiation Therapy, Potential Indications, and Benefits in Lung Cancer**
Ana Botero, United States
- 15:00 Discussion**

14:15-15:15 **SS.08: Combined Modality Therapy**

Grand Ballroom C2

Chairs: Gustavo Ferraris, Argentina, Tannia Soria Samaniego, Ecuador

- 14:15 Combining Radiation Therapy with Targeted Therapy in Oligometastatic Disease**
Andres Cardona, Colombia

- 14:30 Radiation Therapy Combined With Immunotherapy for Unresectable NSCLC**
Clarissa Mathias, Brazil

- 14:45 Radiation Therapy Combined with Immunotherapy as Neoadjuvant Approach**
Ticiana Leal, United States

- 15:00 Discussion**

15:15 - 16:15 Networking Break and Poster Viewing I Grand Ballroom C3 *Refreshments will be provided*

16:15-17:15 **SS.09: Poster Discussion #1**

Grand Ballroom C1

Chairs: Luis Mas, Perú, Heather Wakelee, United States

- 16:15 PD.01.01 - Acquired EGFR Resistant Mutations and Co-mutations in Tumors Of Non-small Cell Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors (TKI)**
Luis E. Raez, United States
- 16:20 PD.01.02 - Novel MicroRNAs Identified in Lung Cancer and Associated With Malignant Metabolism (In Silico)**
Ana Laura Seneda, Brazil
- 16:25 PD.01.03 - Genomic Landscape of Primary-Resistance to Osimertinib among Hispanic Patients With EGFR-Mutant Non-Small-Cell Lung Cancer: Results of an Observational Longitudinal-Cohort Study**
Andres Cardona, Colombia
- 16:30 Posters Discussion**
Rafael Rosell, Spain
- 16:40 PD.01.04 - Rate of Pathogenic Germline Variants Detected in ctDNA Among Patients With Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population**
Samuel Kareff, United States
- 16:45 PD.01.05 - Expanding Lung Cancer Education and LungMATCH, a Treatment and Trial Navigation Program, in a Culturally Sensitive Way with Nuestra Gente**
Renee Botello, United States
- 16:50 Posters Discussion**
Paul Bunn, United States
- 17:00 Discussion**

16:15-17:15 **SS.10: Poster Discussion #2**

Grand Ballroom C2

Chairs: Oscar Arrieta, México, Tannia Soria Samaniego, Ecuador

- 16:15 PD.02.01 - High Extracellular Vesicle TGF- & PD-L1 Predict Poor Outcomes in Patients With Non-small Cell LungCancer Undergoing Immune-Checkpoint Inhibitors**
Diego De Miguel Perez, United States
- 16:20 PD.02.02 - Lung TS: A New 6-Gene Signature for Prediction of Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Patients**
Letícia Ferro Leal, Brazil

THURSDAY | JANUARY 26, 2023

- 16:25 PD.02.03 - Alterations in the Immune Profile of LUSC and LUAD Detected by a Neural Network May Reveal New Immunotherapy Targets**
Iael Weissberg, Brazil
- 16:30 Posters Discussion**
David R. Gandara, United States
- 16:40 PD.02.04 - A Prognostic Value of 3 Gene Sets for Ever-Smokers With Non-small Cell Lung Cancer From Brazil**
Isabella Lemuqui Tegami, Brazil
- 16:45 PD.02.05 - EGFR Exon 20 Insertion Mutations in a Brazilian Lung Cancer Cohort: Challenges for the Identification and Clinical Features**
Isabella Santos Negreiros, Brazil
- 16:50 PD.02.06 - Intensified Chemo-Immuno-Radiotherapy With Durvalumab for Stage III NSCLCS: A Brazilian Single Arm Phase I Study - Pacific Brazil (LACOG 2218)**
William Nassib William Junior, Brazil
- 16:55 Posters Discussion**
David Carbone, United States
- 17:05 Discussion**



FRIDAY | JANUARY 27, 2023

07:30-08:30 IASLC Women in Thoracic Oncology

Grand Ballroom C2

Chairs: Karen Kelly, United States, Clarissa Mathias, Brazil, Heather Wakelee, United States

- 07:30 Opening Remarks**
Karen Kelly, United States
- 07:35 How can We Inspire Other Women to Become Leaders?**
Heather Wakelee, United States
- 07:50 Empowering Women- What are We Achieving?**
Clarissa Mathias, Brazil
- 08:05 Panel Discussion**
Clarissa Mathias, Brazil
Heather Wakelee, United States
Karen Kelly, United States
Lucia Viola, Colombia

08:30-09:30 SS.11: New Developments in Targeted Therapy of Other Thoracic Malignancies

Grand Ballroom C1

Chairs: Luis Mas, Perú, Eduardo Richardet, Argentina

- 08:30 Is There a Targeted Therapy for SCLC**
William Nassib William Junior, Brazil
- 08:45 Mesothelioma: Challenges in Diagnosis and Therapeutic Outlook**
Gelenis Domingo, United States
- 09:00 Biological Insights and Novel Therapy for Malignant Thymoma**
Luis Corrales, Costa Rica
- 09:15 Discussion**

09:45-10:45 SS.12: Presidential Symposium

Grand Ballroom C1

Chairs: Luis Ubillos, Uruguay, Mario Varangot, Uruguay

- 09:45 PSP.01 - Disruptive and Truncating TP53 Mutations Are Frequent in Lung Adenocarcinoma Patients With African Ancestry and Show Worse Prognosis**
Rodrigo de Oliveira Cavagna, Brazil
- 09:55 PSP.02 - Using DNA Next-Generation Sequencing in blood to Guide Therapy for Newly Diagnosed Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients**
Luis E. Ruez, United States
- 10:05 PSP.03 - 12-Gene Expression Signature: A Potential Key for Predicting Prognosis and Benefit to ACT for Resectable NSCLC Patients**
Aléxia Siqueira, Brazil
- 10:15 Presidential Symposium Discussion**
David R. Gandara, United States
- 10:30 Discussion**

10:45 - 11:45 Networking Break and Poster Viewing I Grand Ballroom C3
Refreshments will be provided

11:45-12:45 Round Table Discussions

Grand Ballroom C1

Chairs: Clarissa Baldotto, Brazil, Eduardo Richardet, Argentina

- Table Discussion 1 - Early Stage Lung Cancer: Adjuvant Treatment**
Carlos Barrios, Brazil
Norma Graciela Pilnik, Argentina
Edgardo Santos, United States

Table Discussion 2 - Novel Approaches in Surgery (Robotic Surgery, VATS, Navigation System)

Ricardo Sales dos Santos, Brazil

Francisco Tarrazzi, United States

Ricardo Mingarini Terra, Brazil

Table Discussion 3 - Treatment of Wild Type Lung Cancer Tumors (First and Second Line)

Paul Bunn, United States

Carlos Carracedo, Perú

Table Discussion 4 - Therapy of Tumors Carrying EGFR Mutations

Luis Corrales, Costa Rica

Karen Kelly, United States

Rafael Rosell, Spain

Table Discussion 5 - ALK Positive Tumors: Therapies

Rossana Ruiz, Perú

Ticiane Leal, United States

Gelenis Domingo, United States

Table Discussion 6 - How to Study Molecular Biology and Tumor Markers

Fred R. Hirsch, United States

Ignacio Wistuba, United States

Table Discussion 7 - New Molecules and Therapies for Lung Cancer

Claudio Martin, Argentina

David R. Gandara, United States

Oscar Arrieta, México

Table Discussion 8 - Oligometastatic Lung Cancer

Beatriz Amendola, United States

Ana Botero, United States

William Nassib William Junior, Brazil

Table Discussion 9 - Diagnosis and Staging in Lung Cancer

Lucia Viola, Colombia

Luis Ubillos, Uruguay

Table Discussion 10 - Locally Advanced Lung Cancer

Luis Mas, Perú

Table Discussion 11 - Immunotherapy in Non-small Lung Cancer in Early Stage

Clarissa Mathias, Brazil

Luis E. Raez, United States

Table Discussion 12 - Liquid Biopsy

Christian Rolfo, United States

Maria Arcila, United States

Table Discussion 13 - Uncommon Oncology Drivers: ROS1, BRAF, NTRK, MMR, RET

Alberto Chiappori, United States

Andres Cardona, Colombia

Table Discussion 14 - Small Cell Lung Cancer

Elizabeth Ravera, United States

Clarissa Baldotto, Brazil

Diego Touya, Uruguay

13:00 - 14:00 Lunch Break I Grand Ballroom C3
Refreshments will be provided

14:15-16:00 SS.13: Targeted Therapy & Angiogenesis

Grand Ballroom C1

Chairs: Oscar Arrieta, México, Carlos Carracedo, Perú

14:15 EFGR Exon 20 and Other Uncommon Mutations

Heather Wakelee, United States

14:25 ALK Genomic Aberrations

Fred R. Hirsch, United States

14:35 cMET/BRAF/HER-2/3 Inhibitors

Paul Bunn, United States

14:45 ROS-1 Translocations

Christian Rolfo, United States

14:55 NTRK and NRG1 Fusion Proteins

Luis E. Raez, United States

15:05 New Insights of EGFR Inhibition and Mechanisms of TKI Resistance

Rafael Rosell, Spain

15:15 EGFR/ALK TKIs with Central Nervous System Penetration

Claudio Martin, Argentina

15:25 KRAS and STK11 Mutations and Co-Mutations

Alberto Chiappori, United States

15:35 Discussion

14:15-16:00 SS.14: Immunotherapy

Grand Ballroom C2

Chairs: Luis Mas, Perú, Clarissa Baldotto, Brazil

14:15 Front Line Immunotherapy Only for NSCLC: What is New?

Luis Corrales, Costa Rica

14:25 Immunotherapy Combinations No More Chemotherapy

Ticiane Leal, United States

14:35 Immunotherapy Resistance and Agents

David R. Gandara, United States

14:45 Molecular Markers for Immunotherapy

Andres Cardona, Colombia

14:55 Immunotherapy in SQCC: The Time Has Arrived

Luis Mas, Perú

15:05 Small Cell Lung Cancer Immunotherapy

William Nassib William Junior, Brazil

15:15 Immunotherapy and Oligometastatic Disease

Karen Kelly, United States

15:25 Discussion

16:05-16:30 Closing Ceremony with Education Awards Presentations

Grand Ballroom C1

Chairs: Carlos Barrios, Brazil, Luis Ubillos, Uruguay, Mario Varangot, Uruguay

Education Awards Presentations Introducing LALCA 2024

Andres Cardona, Colombia

Tannia Soria Samaniego, Ecuador

Lucia Viola, Colombia



05



Poster Listing

#LALCA23



Poster Listing

PP.01 - PP.17: Advanced NSCLC

PP.01 - Study Evaluating Alectinib Pharmacokinetics in the Hispanic Population With Advanced ALK-Rearranged Non-small-Cell Lung Cancer

Oscar Arrieta, México

PP.02 - Tyrosine Kinase Inhibitor (TKI) Real-World Use in Epidermal Growth Factor Receptor Mutated (EGFRm) Advanced Non-small Cell Lung Cancer (NSCLC) Patients

Lucía Kaminszczyk, Argentina

PP.03 - Gender Differences in Lung Cancer in Chile

Diego Carrillo, Chile

PP.04 - EGFR Structure-Based Classification and Presence of Commutations in Peruvian Patients With Advanced Lung Cancer

Luis Mas, Perú

PP.05 - Access to Genomic Testing and Targeted Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Single-Institution Study

Berenice Freile, Argentina

PP.06 - Real-World Study of EGFR-TKIs Combined With Radiotherapy in Patients With Brain Metastases From Non-small Cell Lung Cancer

Yi Liu, China

PP.07 - Preliminary Results of a Western Mexican Cohort of Metastatic NSCLC and frequency of ALK, EGFR and PD-L1

Mauricio de Jesús Mora Pineda, México

PP.08 - Analysis of the Status of Tumor-Infiltrating Lymphocytes (TILS) In Patients With NSCLC

Eduardo Richardet, Argentina

PP.09 - Neutrophil Lymphocyte Ratio as a Prognostic Factor in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Eduardo Richardet, Argentina

PP.10 - Role of the Neutrophil-Lymphocyte Relationship in Patients With Advanced NSCLC Treated With Immunotherapy

Eduardo Richardet, Argentina

PP.11 - Effectiveness of Ramucirumab Plus Docetaxel for Advanced Non-Small Cell Lung Cancer Patients: a Cohort of 93 Patients

Isabella Favato Barcelos, Brazil

PP.12 - Access to Molecular Testing and Factors to Implement Targeted Therapy in a Brazilian Public Health Service

Luma Princess Schneider, Brazil

PP.13 - Aptamers as Novel Diagnostic Tools for Lung Cancer Detection

Yuli Yohana Serna Torres, Brazil

PP.14 - Real World Data of Patients ≥ 80 Years Old With Metastatic NSCLC: Evaluation of an Underrepresented Population in Clinical Trials

Filipe Visani, Brazil

PP.15 - Efficacy and Safety of PD-1 Monoclonal Antibody in the Real World

Yaning Zhu, China

PP.16 - Evaluation of Pathogenicity and in Silico Analysis of HERC2 Variants in Non-Small Cell Lung Cancer

Letícia Ferro Leal, Brazil

PP.17 - Stereotactic Ablative Radiotherapy in Oligometastatic Pulmonary Disease. First Institutional Experience

Gustavo Ferraris, Argentina

PP.18 - PP.26: Biology and Pathogenesis, Pathology

PP.18 - Cellular Foundations of Radiotherapy Protocols Frequently Used in Pulmonary Pathology

Gustavo Ferraris, Argentina

PP.19 - Methylation Profile of Non-Small Cell Lung Cancer of Brazilian Patients

Letícia Ferro Leal, Brazil

PP.20 - Concordance of Actionable Mutations in Liquid Biopsies and Matched Tumor Tissue of Brazilian Non-small Cell Lung Cancer (NSCLC)

Letícia Ferro Leal, Brazil

Poster Listing

PP.21 - Genomic Landscape of Admixed Non-small Cell Lung Cancer: A Series of Brazilian Single-Center

Letícia Ferro Leal, Brazil

PP.22 - Mutational Profile of Never-Smoker Patients With Lung Adenocarcinoma From a Single-Center in Brazil

Rodrigo de Oliveira Cavagna, Brazil

PP.23 - GALNT13 Detection in Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC) Patients

Eugenia Fernandez Armua, Uruguay

PP.24 - High Correlation With KRAS and PDL-1 in Lung Adenocarcinoma of a Single Institution

Bruna Motke, Brazil

PP.25 - Quality of the Tissue Sample in the Determination of the Molecular Profile of Lung Cancer. Our Experience

Norma Graciela Pilnik, Argentina

PP.26 - Immunoexpression of 4 Different PD-L1 Clones in NSCLC Cases, a Comparative Study From Northeastern Brazil

Fabio Tavora, Brazil

PP.27 - PP.36: Early Stage NSCLC (Stage I - III)

PP.27 - Clinical Outcomes of Stage III Non-small Cell Lung Cancer Patients Treated With Radical Radiotherapy in a Institution in Brazil

Denize Bodnar, Brazil

PP.28 - Underutilization of Systemic Therapy in Patients Undergoing Pneumonectomy: A Missed Opportunity for Survival

Jorge Humberto Rodriguez Quintero, United States

PP.29 - Management of Lung Cancer During the COVID-19 Pandemic: Experience of a High Complexity Center in Medellin-Colombia

Ricardo Zapata Gonzalez, Colombia

PP.30 - Comparing the Most Influential Publications on Robotic-Assisted Pulmonary Lobectomy and on Robotic-Assisted Pulmonary Segmentectomy

Eric Toloza, United States

PP.31 - Marital Status Shows No Protective Effect on Perioperative Outcomes After Robotic-Assisted Pulmonary Lobectomy

Eric Toloza, United States

PP.32 - Postoperative Serum Magnesium Levels and Outcomes Following Robotic-Assisted Pulmonary Lobectomy

Eric Toloza, United States

PP.33 - Effect of Age on Incidences of Peri-Operative Outcomes after Robotic-Assisted Video-Thoroscopic Pulmonary Lobectomy

Allison Dumitriu Carcoana, United States

PP.34 - Impact of Cardiac Comorbidities on Perioperative Outcomes After Robotic-Assisted Pulmonary Lobectomy

Allison Dumitriu Carcoana, United States

PP.35 - Preoperative Blood-Urea-Nitrogen-to-Serum-Albumin Ratio Is Not a Predictor of Worse Outcomes After Robotic-Assisted Pulmonary Lobectomy for Lung Cancer

Allison Dumitriu Carcoana, United States

PP.36 - Thoracoscopic Limited Resection in Lung Adenocarcinoma, 4 Years Disease-Free Survival

Emmanuel Peña Gomez Portugal, México

PP.37 - PP.40: SCLC, Mesothelioma, Thymoma

PP.37 - Thymic Neuroendocrine R0 Surgery

Emmanuel Peña Gomez Portugal, México

PP.38 - Unusual Location of Thymic Carcinoma and It's Surgical Management

Emmanuel Peña Gomez Portugal, México

PP.39 - Helical Tomotherapy for Primary and Secondary Malignant Pleural Tumors

Marija Jankova, Bulgaria

PP.40 - Phase II Clinical Study: Whole-Brain Radiotherapy Plus Sequential or Simultaneous Integrated Boost for the Treatment of Brain Metastases in NSCLC

Dai Yuan Ma, China

Poster Listing

PP.41 - PP.44: Immunotherapy

PP.41 - Novel Synthetic Extracellular Vesicles as a Chemotherapeutic Carrier for Potential Lung Cancer Treatment

Javiera Carrasco-Rojas, Chile

PP.42 - Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLC

Byoung Chul Cho, Korea

PP.43 - Retrospective Analysis of Serum Parameters in Patients Treated With Check-Point Inhibitors in 2ND Line for Advance Non-small-Cell Lung Cancer

Pablo Flores Paco, Spain

PP.44 - Immune-Checkpoint Inhibitors: Biomarkers to Predict Response to Immunotherapy in Non-small Cell Lung Cancer Patients

Katiane Tostes, Brazil

PP.45 - PP.46: Nursing & Allied Health & Patient Advocacy & Supportive Care

PP.45 - Understanding Therapeutic Trajectories of Adults With Lung Cancer in Chile: A Multi-Methods Study of Time to Diagnosis and Perceived Experience

Carla Campaña, Chile

PP.46 - The Impact of Multidisciplinary Teams on the Diagnosis and Staging of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Gilberto Castro Junior, Brazil

PP.47 - PP.53: Prevention, Early Detection, Epidemiology and Tobacco Control

PP.47 - Lacking Representation of Hispanics in Lung Cancer Screening Trials

Caio Heleno, United States

PP.48 - Breakthrough SARS-CoV-2 Infection and COVID-19 Disease Severity in Lung Cancer Patients

Diego De Miguel Perez, United States

PP.49 - Use of Ultrasound Guidance in Thoracic Surgery Biopsies in Lung Cancer

Macarena Muto, Uruguay

PP.50 - Implementation of an Institutional Lung Cancer Screening Program Using Low-Dose Computed Tomography in Argentina

María Delfina Peralta Tanco, Argentina

PP.51 - Cost-Effectiveness Study of Lung Cancer Screening in Uruguay (UY-LUNGS)

Virginia Rodriguez Sande, Uruguay

PP.52 - Current status of Lung Cancer Screening in Latin America

Lucia Viola, Colombia

PP.53 - Lung Cancer in Peru: A Disease of Never Smokers

Rossana Ruiz, Perú





06



Education Awards



#LALCA23



Education Awards

Congratulations to the LALCA 2023 Education Award Winners!

Award Winners will be presented with their award during the **Closing Ceremony** on **Friday, January 27** from **16:05 – 16:30** in **Grand Ballroom C1**.

Diego De Miguel Perez

Icahn School Of Medicine At Mount Sinai New York, United States

PD.02.01: High Extracellular Vesicle TGF- β & PD-L1 Predict Poor Outcomes in Patients With Non-small Cell Lung Cancer Undergoing Immune-Checkpoint Inhibitors

SS.10: Poster Discussion #2

Thursday, January 26 | 16:15 – 17:15

Grand Ballroom C2

Ana Laura Seneda

Faculty Of Medicine, São Paulo State University (UNESP), Brazil

PD.01.02: Novel MicroRNAs Identified in Lung Cancer and Associated With Malignant Metabolism (In Silico)

SS.09: Poster Discussion #1

Thursday, January 26 | 16:15 – 17:15

Grand Ballroom C1

Aléxia Siqueira

Molecular Oncology Research Center, Barretos Cancer Hospital, Brazil

PSP.03: 12-Gene Expression Signature: A Potential Key for Predicting Prognosis and Benefit to ACT for Resectable NSCLC Patients

SS.12: Presidential Symposium

Friday, January 27, 09:45 – 10:45

Grand Ballroom C1

Samuel Kareff

University Of Miami Sylvester Comprehensive Cancer Center/ Jackson Memorial Hospital, United States

PD.01.04: Rate of Pathogenic Germline Variants Detected in ctDNA Among Patients With Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population

SS.09: Poster Discussion #1

Thursday, January 26 | 16:15 – 17:15

Grand Ballroom C1

Rodrigo de Oliveira Cavagna

Barretos Cancer Hospital, Brazil

PSP.01: Disruptive and Truncating TP53 Mutations Are Frequent in Lung Adenocarcinoma Patients With African Ancestry and Show Worse Prognosis

SS.12: Presidential Symposium

Friday, January 27, 09:45 – 10:45

Grand Ballroom C1



07



Industry Supporters & Exhibitors



#LALCA23



Industry Supporters and Exhibitors

The IASLC 2023 Latin America Conference on Lung Cancer would like to thank the following companies for their support:








Supporters Lists

BRONZE LEVEL



Industry Supporters and Exhibitors

EXHIBITOR	DESCRIPTION
	<p>Caris Life Sciences® is the leading molecular science and technology company developing innovative solutions to revolutionize healthcare and improve patient outcomes. With a primary focus on cancer, Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients.</p> <p>www.carislifesciences.com</p>
	<p>At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart.</p> <p>www.janssenpro.com</p>
	<p>Seagen is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. For more information visit www.seagen.com</p>
	<p>At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 11,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit www.varian.com and follow @VarianMedSys on Twitter</p>
	<p>The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. Since its founding in 1974, the association's membership has grown to more than 8,000 lung and thoracic cancer specialists from all disciplines and more than 100 countries.</p> <p>By hosting global conferences, funding cutting-edge research, and educating the health care community and the public about thoracic cancers, the IASLC works to alleviate the burden lung cancer places on patients, families, and communities.</p>

04

General Information

#LALCA23



General Information

HEALTH & SAFETY MEASURES

LALCA 2023 will be hosted as an in-person meeting. The health and safety of all our stakeholders are of the utmost importance. Although we are excited to welcome you to LALCA 2023, all necessary precautions will be taken to ensure a safe environment throughout the Conference. The following measures will be put in place to achieve this commitment (applicable to all staff, delegates, exhibitors, sponsors, and guests):



VACCINATION POLICY

IASLC recommends that all in-person attendees are fully vaccinated against COVID-19 by the time of the Conference. Fully vaccinated refers to completing the approved first 2 vaccines, as per the guidelines of their country of residence. IASLC will, however, not require proof of vaccination prior or during the Conference.



MASKS AND FACE COVERINGS

Masks will be encouraged to be worn at LALCA 2023. By attending, you agree that:

- You have no COVID-19 symptoms
- If during your attendance you develop any COVID-19 symptoms, you will immediately:
 - Self-isolate;
 - Comply with all local/national government restrictions; and
 - Inform the LALCA 2023 Conference Secretariat by email (lalca2023-registration@icsevents.com).

IASLC and their suppliers will, in their best effort, provide a safe environment to meet. It is expected that all participants will follow the measures to help reduce the risk.

Please note: There will be no on-site testing facility available at LALCA 2023.




WI-FI

Network: LALCA2023
Password: LALCA2023

OPENING HOURS

Registration Desk

 **Foyer, 2nd Floor**

Wednesday, January 25	08:00 - 19:30
Thursday, January 26	08:00 - 16:30
Friday, January 27	07:00 - 14:30

Poster Viewing & Networking

 **Grand Ballroom C3, 2nd Floor**

Thursday, January 26	09:30 - 10:30 15:30 - 16:30
Friday, January 27	10:45 - 11:45

Exhibit Hours

 **Grand Ballroom C3, 2nd Floor**

Wednesday, January 25	19:30 - 20:30 Welcome Reception
Thursday, January 26	09:30 - 16:30
Friday, January 27	10:30 - 14:00



ACCESS/SECURITY

Attendees are requested to wear their name badges at all times in order to participate in the Scientific Sessions and Exhibition. A 50 USD fee applies for any name badge reprints due to lost name badges.



LOST AND FOUND / MESSAGES

Lost and found items should be returned / claimed at the Registration Desk.



2023 World Conference on Lung Cancer

SEPTEMBER 9-12, 2023 | SINGAPORE

Save the Date!

Join us for WCLC 2023 in Singapore!

Abstract Submissions will open in January 2023.

Showcase your research and contribute to discussions that will shape the future of treatments in lung cancer and thoracic malignancies.

CONNECT WITH US



@IASLC



facebook.com/IASLC



@iaslungcancer



linkedin.com/IASLC



IASLC

#WCLC23

WLCL2023.IASLC.org

IASLC 2022-23

MEETINGS SCHEDULE

IASLC 2023 Targeted Therapies of Lung Cancer Meeting

February 22-25, 2023
Santa Monica, California
#TTL23

IASLC 2023 Hot Topic Meeting: Small Cell Lung Cancer

April 5-7, 2023
New York, New York
#SCLC23

IASLC 2023 World Conference on Lung Cancer

September 9-12, 2023
Singapore
#WCLC23



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide

[IASLC.org/Meetings-Webinars](https://iaslc.org/Meetings-Webinars)

Scan the
QR code for
information
on upcoming
meetings and
webinars.



CONNECT WITH US

 @IASLC

 facebook.com/IASLC

 @iaslungcancer

 linkedin.com/IASLC

 IASLC

* Location and dates subject to change



Join the IASLC Today!



Scan the QR code
& enter

LALCANewMember2023

to receive half off
membership dues
for one year.



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide



IASLC
Meeting
Discounts

Patient
Advocacy

Podcasts

Publications

ILCN

Networking

Research &
Education

Scientific
Expertise

IASLC
Journals

Membership

ILC
Foundation

Staging

Committees

